6881

COM:VAZYME

诺唯赞

  • Stock

CNY

Last Close

23.50

25/11 07:00

Market Cap

8.03B

Beta: -

Volume Today

2.19M

Avg: -

Company Overview

Metric
Company NameNanjing Vazyme Biotech Co., Ltd.中国生物技术股份有限公司
Symbol688.11K
MSH IDCOM:VAZYMECN:COM:CNBG
MarketSTOCKSPRIVATE
SectorHealthcareHealthcare & Health Services
IndustryBiotechnologyBiotechnology
CountryCNCN
StageSeries C
Employee Count2.70K
Websitevazyme.comcnbg.com.cn
LinkedInvazymechina-national-biotec-group-company-limited
Founders

Market Metrics

Metric
Market Cap1.10B
Enterprise Value
Monthly Web Traffic1.61K
Web Traffic Growth-0.40
Valuation
Raised Capital84.21M

Financial Performance

Metric
Revenue177.00M
Revenue (LTM)
Revenue (NTM)
Gross Profit177.00M
EBITDA-7.52M
Operating Income-13.74M
Net Income-9.72M
EPS-0.02
Diluted EPS-0.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Growth Metrics

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Profitability Ratios

Metric
Gross Profit Margin0.80
Operating Profit Margin-0.05
EBITDA Margin-0.04
Net Profit Margin0.02
Return on Equity0.01
Return on Assets0.01
Return on Capital Employed-0.02

Valuation Multiples

Metric
P/E Ratio-31.42
P/B Ratio1.82
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio8.68
EV Multiple393.78

Operational Metrics

Metric
Days Sales Outstanding58.74
Days Payables Outstanding80.75
Days Inventory Outstanding600.52
Operating Cycle697.89
Cash Conversion Cycle462.35
Asset Turnover0.27

Cash Flow Metrics

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt0.19
Operating Cash Flow/Sales0.16
Free Cash Flow Yield-0.07

Balance Sheet Metrics

Metric
Cash & Equivalents270.54M
Accounts Receivable
Inventory47.63M
Goodwill17.95M
Debt to Capitalization0.25
Debt to Assets0.23
Current Ratio2.76
Quick Ratio4.09

Efficiency Metrics

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue0.17
SG&A to Revenue0.05